Amicogen, Inc.

KOSDAQ 092040.KQ

Amicogen, Inc. Shareholders' Equity for the year ending December 31, 2023: USD 135.05 M

Amicogen, Inc. Shareholders' Equity is USD 135.05 M for the year ending December 31, 2023, a 29.70% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Amicogen, Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 104.12 M, a -33.18% change year over year.
  • Amicogen, Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 155.82 M, a 10.98% change year over year.
  • Amicogen, Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 140.40 M, a 33.45% change year over year.
  • Amicogen, Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 105.21 M, a -7.55% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
KOSDAQ: 092040.KQ

Amicogen, Inc.

Description

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, chemical, and energy industries. It also provides new bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides; and lactic acid bacteria, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. In addition, the company offers K-nutra, a healthcare brand; and KeyClean, a disinfectant brand. Further, it provides protein purification resins. The company was founded in 2000 and is headquartered in Jinju-si, South Korea.

Similar companies

196170.KQ

ALTEOGEN Inc.

USD 240.05

-5.25%

039130.KS

Hanatour Service Inc.

USD 36.84

-3.71%

078340.KQ

Com2uS Corporation

USD 31.73

-1.83%

StockViz Staff

February 4, 2025

Any question? Send us an email